JP2015518828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518828A5 JP2015518828A5 JP2015512753A JP2015512753A JP2015518828A5 JP 2015518828 A5 JP2015518828 A5 JP 2015518828A5 JP 2015512753 A JP2015512753 A JP 2015512753A JP 2015512753 A JP2015512753 A JP 2015512753A JP 2015518828 A5 JP2015518828 A5 JP 2015518828A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- acid
- zoledronic acid
- appendix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims description 87
- 229960004276 zoledronic acid Drugs 0.000 claims description 84
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 84
- 241000124008 Mammalia Species 0.000 claims description 38
- 208000002193 Pain Diseases 0.000 claims description 32
- 230000003442 weekly effect Effects 0.000 claims description 22
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 18
- 229940127557 pharmaceutical product Drugs 0.000 claims description 18
- 206010065390 Inflammatory pain Diseases 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 16
- 230000002917 arthritic effect Effects 0.000 claims description 11
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 8
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 8
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 8
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 8
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 8
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002286 clodronic acid Drugs 0.000 claims description 8
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 8
- 229960004585 etidronic acid Drugs 0.000 claims description 8
- 229960005236 ibandronic acid Drugs 0.000 claims description 8
- 229950006971 incadronic acid Drugs 0.000 claims description 8
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 8
- 229950004969 olpadronic acid Drugs 0.000 claims description 8
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 8
- 229960003978 pamidronic acid Drugs 0.000 claims description 8
- 229960005324 tiludronic acid Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000001387 Causalgia Diseases 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 229960004343 alendronic acid Drugs 0.000 claims 4
- 229950010733 neridronic acid Drugs 0.000 claims 4
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims 4
- 229960000759 risedronic acid Drugs 0.000 claims 4
- 239000002253 acid Substances 0.000 description 4
- 229940062527 alendronate Drugs 0.000 description 4
- 229940089617 risedronate Drugs 0.000 description 4
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646538P | 2012-05-14 | 2012-05-14 | |
| US61/646,538 | 2012-05-14 | ||
| US201261647478P | 2012-05-15 | 2012-05-15 | |
| US61/647,478 | 2012-05-15 | ||
| US201261654292P | 2012-06-01 | 2012-06-01 | |
| US201261654383P | 2012-06-01 | 2012-06-01 | |
| US61/654,383 | 2012-06-01 | ||
| US61/654,292 | 2012-06-01 | ||
| US201261655541P | 2012-06-05 | 2012-06-05 | |
| US201261655527P | 2012-06-05 | 2012-06-05 | |
| US61/655,527 | 2012-06-05 | ||
| US61/655,541 | 2012-06-05 | ||
| US201361762225P | 2013-02-07 | 2013-02-07 | |
| US61/762,225 | 2013-02-07 | ||
| US201361764563P | 2013-02-14 | 2013-02-14 | |
| US61/764,563 | 2013-02-14 | ||
| US201361767676P | 2013-02-21 | 2013-02-21 | |
| US201361767647P | 2013-02-21 | 2013-02-21 | |
| US61/767,676 | 2013-02-21 | ||
| US61/767,647 | 2013-02-21 | ||
| US201361803721P | 2013-03-20 | 2013-03-20 | |
| US61/803,721 | 2013-03-20 | ||
| PCT/US2013/040939 WO2013173330A1 (en) | 2012-05-14 | 2013-05-14 | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018075822A Division JP2018127477A (ja) | 2012-05-14 | 2018-04-11 | 経口医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015518828A JP2015518828A (ja) | 2015-07-06 |
| JP2015518828A5 true JP2015518828A5 (https=) | 2016-06-30 |
Family
ID=49549077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512753A Pending JP2015518828A (ja) | 2012-05-14 | 2013-05-14 | 炎症性疼痛および関連症状を緩和するためのゾレドロン酸または関連化合物を含む組成物 |
| JP2018075822A Pending JP2018127477A (ja) | 2012-05-14 | 2018-04-11 | 経口医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018075822A Pending JP2018127477A (ja) | 2012-05-14 | 2018-04-11 | 経口医薬組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20130303486A1 (https=) |
| EP (2) | EP2849758B1 (https=) |
| JP (2) | JP2015518828A (https=) |
| KR (3) | KR20150035597A (https=) |
| CN (2) | CN109331027A (https=) |
| AU (3) | AU2013262995B2 (https=) |
| CA (2) | CA2873742C (https=) |
| CY (1) | CY1120503T1 (https=) |
| DK (1) | DK2849758T3 (https=) |
| ES (1) | ES2667535T3 (https=) |
| HK (1) | HK1255373A1 (https=) |
| HR (1) | HRP20180606T1 (https=) |
| HU (1) | HUE038905T2 (https=) |
| LT (1) | LT2849758T (https=) |
| NZ (1) | NZ702414A (https=) |
| PL (1) | PL2849758T3 (https=) |
| PT (1) | PT2849758T (https=) |
| RS (1) | RS57294B1 (https=) |
| SI (1) | SI2849758T1 (https=) |
| SM (1) | SMT201800212T1 (https=) |
| WO (1) | WO2013173330A1 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| DK2459176T3 (en) | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US8802658B2 (en) | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
| US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
| US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
| US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9427403B2 (en) | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
| US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| WO2015184003A1 (en) * | 2014-05-27 | 2015-12-03 | Antecip Bioventures Ii Llp | Osteoclast inhibitors for pain |
| US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
| US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9289441B2 (en) | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
| US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
| CN104969556A (zh) | 2013-01-08 | 2015-10-07 | Lg电子株式会社 | 处理视频信号的方法和设备 |
| SG10201609548UA (en) * | 2013-10-25 | 2016-12-29 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| CN106456610A (zh) * | 2014-05-27 | 2017-02-22 | 安泰赛普生物风投二代有限责任公司 | 用于疼痛的破骨细胞抑制剂 |
| CA2950443A1 (en) * | 2014-05-27 | 2015-12-03 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for pain |
| US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
| KR20210149861A (ko) * | 2014-05-27 | 2021-12-09 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 통증용 파골 세포 억제제 |
| US20170182072A1 (en) * | 2014-05-27 | 2017-06-29 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9079927B1 (en) | 2014-05-27 | 2015-07-14 | Antecip Bioventures Ii Llc | Substituted imidazolium compounds for treating disease |
| US9688765B2 (en) | 2014-06-11 | 2017-06-27 | Antecip Bioventures Ii Llc | Methods using RANK/RANKL antagonist antibodies for treating pain |
| SI3206694T1 (sl) * | 2014-10-15 | 2020-11-30 | Abiogen Pharma Spa | Uporaba neridronske kisline ali njene soli za zdravljenje osteoartroze |
| MX2018002627A (es) * | 2015-09-18 | 2018-12-17 | Gruenenthal Chemie | Metodo de cristalizacion y biodisponibilidad. |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| US20190328755A1 (en) * | 2018-04-30 | 2019-10-31 | Grunenthal Gmbh | Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid |
| CN109908159B (zh) * | 2019-03-15 | 2021-12-07 | 暨南大学 | 唑来膦酸和有机硒化合物联用在制备抗肿瘤药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639338A (en) * | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
| US6579860B1 (en) * | 1998-12-25 | 2003-06-17 | Toray Industries, Inc. | Interleukin-6 production inhibitors |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| US7875597B2 (en) * | 2002-07-24 | 2011-01-25 | New York University | Treatment of spinal mechanical pain |
| CN1705485A (zh) * | 2002-10-15 | 2005-12-07 | 诺瓦提斯公司 | 施用双膦酸类化合物的方法 |
| EP1612212A1 (en) * | 2003-07-03 | 2006-01-04 | Teva Pharmaceutical Industries Ltd | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| AR046773A1 (es) * | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| JPWO2005072747A1 (ja) * | 2004-02-02 | 2007-09-13 | 小野薬品工業株式会社 | 骨吸収抑制剤 |
| KR20060134216A (ko) * | 2004-04-16 | 2006-12-27 | 에미스페어 테크놀로지스, 인코포레이티드 | 활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염 |
| JP2007536235A (ja) * | 2004-05-06 | 2007-12-13 | メルク エンド カムパニー インコーポレーテッド | イヌにおいて関節炎状態を治療するための方法 |
| DK2283825T3 (da) * | 2004-05-24 | 2022-06-27 | Theramex Hq Uk Ltd | Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel |
| CN101198316A (zh) * | 2005-03-17 | 2008-06-11 | 伊兰制药国际有限公司 | 纳米微粒双膦酸盐组合物 |
| KR101191322B1 (ko) * | 2006-04-07 | 2012-10-16 | 메리온 리서치 Ⅲ 리미티드 | 증진제를 함유하는 고형 경구용 투여 제형 |
| US20100215743A1 (en) * | 2009-02-25 | 2010-08-26 | Leonard Thomas W | Composition and drug delivery of bisphosphonates |
| WO2011097269A1 (en) * | 2010-02-06 | 2011-08-11 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US8980868B2 (en) * | 2009-07-31 | 2015-03-17 | Thar Pharmaceuticals, Inc. | Oral forms of a phosphonic acid derivative |
-
2013
- 2013-05-14 SM SM20180212T patent/SMT201800212T1/it unknown
- 2013-05-14 CA CA2873742A patent/CA2873742C/en active Active
- 2013-05-14 CA CA2987470A patent/CA2987470A1/en not_active Abandoned
- 2013-05-14 KR KR1020147034760A patent/KR20150035597A/ko not_active Ceased
- 2013-05-14 CN CN201811173434.6A patent/CN109331027A/zh active Pending
- 2013-05-14 JP JP2015512753A patent/JP2015518828A/ja active Pending
- 2013-05-14 KR KR1020167032879A patent/KR20160139050A/ko not_active Ceased
- 2013-05-14 SI SI201330993T patent/SI2849758T1/en unknown
- 2013-05-14 EP EP13791356.2A patent/EP2849758B1/en active Active
- 2013-05-14 ES ES13791356.2T patent/ES2667535T3/es active Active
- 2013-05-14 PL PL13791356T patent/PL2849758T3/pl unknown
- 2013-05-14 HU HUE13791356A patent/HUE038905T2/hu unknown
- 2013-05-14 WO PCT/US2013/040939 patent/WO2013173330A1/en not_active Ceased
- 2013-05-14 US US13/894,252 patent/US20130303486A1/en not_active Abandoned
- 2013-05-14 RS RS20180483A patent/RS57294B1/sr unknown
- 2013-05-14 US US13/894,274 patent/US20130303488A1/en not_active Abandoned
- 2013-05-14 CN CN201380025570.XA patent/CN104349781A/zh active Pending
- 2013-05-14 PT PT137913562T patent/PT2849758T/pt unknown
- 2013-05-14 US US13/894,262 patent/US20130303487A1/en not_active Abandoned
- 2013-05-14 HR HRP20180606TT patent/HRP20180606T1/hr unknown
- 2013-05-14 AU AU2013262995A patent/AU2013262995B2/en active Active
- 2013-05-14 KR KR1020197000076A patent/KR20190004381A/ko not_active Ceased
- 2013-05-14 EP EP17206293.7A patent/EP3323418A1/en not_active Withdrawn
- 2013-05-14 US US13/894,244 patent/US20130303485A1/en not_active Abandoned
- 2013-05-14 DK DK13791356.2T patent/DK2849758T3/en active
- 2013-05-14 LT LTEP13791356.2T patent/LT2849758T/lt unknown
- 2013-05-14 NZ NZ702414A patent/NZ702414A/en unknown
-
2016
- 2016-02-03 US US15/014,994 patent/US20160151398A1/en not_active Abandoned
- 2016-11-08 AU AU2016256701A patent/AU2016256701B2/en active Active
-
2018
- 2018-04-11 JP JP2018075822A patent/JP2018127477A/ja active Pending
- 2018-05-03 CY CY20181100458T patent/CY1120503T1/el unknown
- 2018-08-10 AU AU2018214132A patent/AU2018214132B2/en active Active
- 2018-11-14 HK HK18114512.0A patent/HK1255373A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518828A5 (https=) | ||
| Dunstan et al. | Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease | |
| JP6067466B2 (ja) | 骨粗鬆症の治療および予防用のビスホスホン酸 | |
| CY1125501T1 (el) | Εντερικη στερεη απο του στοματος χορηγουμενη δοσολογικη μορφη ενος διφωσφονικου αλατος που περιεχει εναν χηλικο παραγοντα | |
| Kakehashi et al. | Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings | |
| JP2019536805A5 (https=) | ||
| JP2013500995A5 (https=) | ||
| SI2849758T1 (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| RU2007136046A (ru) | Лекарственные формы ризедроната | |
| min You et al. | Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics | |
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| KR101102364B1 (ko) | 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물 | |
| HUP0302556A2 (hu) | Biszfoszfonátok fájdalomcsillapítóként való alkalmazása | |
| JP2015038135A5 (https=) | ||
| JP2013231087A5 (https=) | ||
| ES2269014T1 (es) | Procedimiento para inhibir la resorcion osea. | |
| Piscitelli et al. | Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. | |
| JP2016505050A5 (https=) | ||
| Venkatasatya et al. | Phosphate buffer-stabilized 0.1% chlorine dioxide oral rinse for managing medication-related osteonecrosis of the jaw | |
| WO2009087553A1 (en) | Kits for administering bisphosphonates | |
| Reginster et al. | Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date | |
| CN101384267A (zh) | 用于治疗转移性骨疼痛的伊本膦酸盐方案 | |
| Bagan | Bisphosphonates/denosumab | |
| Rather et al. | Bisphosphonates in clinical practice | |
| 지연백 et al. | Management of osteoporosis patients for prosthetic restoration |